Which Patients Benefit from Radiation Therapy in Diffuse Large B-Cell Lymphoma in 2023? Recent Evidence and Future Developments
The role of RT in DLBCL is changing. Recent randomized studies have challenged the role of RT in the primary treatment of DLBCL but they included selected patient populations, making application of results in routine clinical practice difficult.
Category
  • Hematologic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
ASTRO/ILROG Joint Session - When Every Centigray Counts: Expert Panelists on Approaching and Optimizing the Most Challenging Lymphoma Plans
Ongoing advances in technology have allowed for the shrinkage of target volumes and lowering of doses in the treatment of lymphomas with radiation.
Category
  • Hematologic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Challenging Cases in Lymphoma - Modern RT for the CAR-T and Advanced Imaging Era
A session of challenging cases in lymphoma with a panel of expert radiation oncologists, including one in private practice, and a lymphoma medical oncologist is presented: (1) Refractory CNS lymphoma – primary or secondary, with plans for, or having completed CAR T-cell therapy.
Category
  • Hematologic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
At the Cutting Edge: The Increasing Role of Salvage Radiotherapy in Relapsed/Refractory Lymphomas
Recently, there have been exciting advances in the treatment of relapsed/refractory (R/R) lymphomas. Historically, the standard-of-care included salvage chemotherapy followed by autologous stem cell transplantation (ASCT). Today, many other salvage options are available.
Category
  • General RO
  • Head and Neck
  • Hematologic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Is Consolidation Radiotherapy Still Needed for Lymphoma in 2024? Reappraisal in Light of Recent Trials Results
Radiotherapy plays an important role as a consolidation treatment after systemic therapy, either to shorten the course of systemic therapy and reduce hematological, cardiac and fertility toxicity or to reduce the risk of relapse e.g., for bulky masses.
Category
  • Hematologic
  • Patient Safety
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
The Role of Radiation in Diffuse Large B-cell Lymphoma in Community Practice
This session provides an in-depth discussion of the role of radiation therapy in Diffuse Large B-cell Lymphoma (DLBCL). This is the most common type of lymphoma seen in a community practice, and, with recent advancements in treatment, the role of radiation therapy is evolving.
Category
  • Hematologic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
How High Can We Go - How Low Should We Aim? Normal Tissue Dose/Volume Constraints in Lymphoma Radiation Therapy Planning
Normal tissue dose-volume constraints are commonly used for lymphoma radiation therapy (RT) planning.
Category
  • Hematologic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00